Healthy Clinical Trial
Official title:
Effects of Topical Anti-Inflammatory Agents on Cutaneous Wound Healing
This study will evaluate the effects of a protein called secretory leukocyte protease
inhibitor (SLPI), on skin wound healing. Produced naturally by the body, SLPI modifies
levels of elastase, a substance that breaks down the skin. Older people are at greater risk
of impaired wound healing, with increased elastase activity and inflammation. In addition,
men heal more slowly than women. Delayed healing is associated with infection and pain and
can lead to the development of chronic non-healing skin wounds.
Healthy men and women between 60 and 80 years old who wish to participate in this study will
have a brief history and physical evaluation to determine their eligibility. Those enrolled
will be randomly assigned to receive a gel form of SLPI applied topically (on the skin
surface) to a skin wound or a placebo (a look-alike gel with no active ingredient).
Participants will undergo the following procedures:
First visit - The skin will be numbed with a local anesthetic and two small (4 mm) wounds
(about the size of a pencil eraser) made in each upper arm. The drug or placebo will be
applied to the wound and gauze placed over it. Two blood samples (20 ml and 7 ml) will be
drawn an hour apart to determine blood levels of SLPI.
Second visit - The day after the first visit, the wound dressing will be removed and the
participant will be evaluated for pain at the wound site, allergic reactions or infection. A
blood sample (7 ml) will be taken.
Third visit - The wounds will be examined and photographed to evaluate healing. In addition,
the strength of the wound may be assessed by means of a vacuum system placed on the skin.
(This may cause a tingling sensation over the wound.) A piece of all four wounds will be
removed after the skin has been numbed and a dressing applied.
Fourth visit - The wounds will be examined for healing and the dressing removed.
Status | Completed |
Enrollment | 60 |
Est. completion date | July 2003 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | N/A and older |
Eligibility |
Healthy subjects will be used in the study to remove bias from associated
pathology/comorbidity. Only Caucasian patients will be included. One group of male volunteers of 60-80 years of age will be used for the pilot study. There will be two groups for the main study: one male and one female group (age-matched equivalent groups). Females will be post-menopausal with the menarche at least 1 year previously and not taking hormone replacement therapy. No patients infected with Hepatitis B, C, non A/B virus or HIV. Pregnancy or lactating females will be excluded. Diabetic patients will be excluded. Patient must not be a smoker; or ex-smoker of greater than 5 per day for over one year. Patients must not be on any regular medication, for example: oral/topical/intra-articular corticosteroids, NSAIDSs, immunosuppressives, chemotherapeutic agents, anti-hypertensives, vasodilators, anti-arthritic agents (gold, azathioprine), antibiotics, and insulin/biguanides/sulphonylureas. Patients must not be taking oral contraceptive or HRT (oral or implant) (main study only). Patients must not have a history of cardiovascular disease, malignancy, stroke, inflammatory bowel disease, Alzheimer's disease, or pulmonary fibrosis/sarcoid/CAPD. Patients must not have presence of anemia, leukocytosis, bleeding disorder, or abnormal renal/liver function. Patients with known keloid former or previous evidence of hypertrophic scarring will be excluded. Patients with presence of skin disorders such as venous ulcers, psoriasis, eczema or lichen planus will be excluded. |
Endpoint Classification: Safety Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Dental And Craniofacial Research (NIDCR) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Dental and Craniofacial Research (NIDCR) |
United States,
Ashcroft GS, Dodsworth J, van Boxtel E, Tarnuzzer RW, Horan MA, Schultz GS, Ferguson MW. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat Med. 1997 Nov;3(11):1209-15. — View Citation
Ashcroft GS, Herrick SE, Tarnuzzer RW, Horan MA, Schultz GS, Ferguson MW. Human ageing impairs injury-induced in vivo expression of tissue inhibitor of matrix metalloproteinases (TIMP)-1 and -2 proteins and mRNA. J Pathol. 1997 Oct;183(2):169-76. — View Citation
Ashcroft GS, Horan MA, Herrick SE, Tarnuzzer RW, Schultz GS, Ferguson MW. Age-related differences in the temporal and spatial regulation of matrix metalloproteinases (MMPs) in normal skin and acute cutaneous wounds of healthy humans. Cell Tissue Res. 1997 Dec;290(3):581-91. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |